Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Predictors of cGVHD Outcomes Remain Elusive in Pediatric Hematologic Malignancies

September 29th 2025

Acute GVHD was shown to be a risk factor for chronic GVHD, but factors such as organ involvement showed no correlation with long-term outcomes.

FDA Clears Guardant360 CDx as Companion Diagnostic for Imlunestrant in ESR1-Mutated Breast Cancer

September 29th 2025

The Guardant360 CDx liquid biopsy test has been approved to identify patients with ESR1-mutated breast cancer who are eligible to receive imlunestrant.

Dr Mulherin on Using AI to Address NGS Testing Barriers in Oncology Practice

September 28th 2025

Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.

From Overload to Insight: Why AI Is Becoming an Essential Partner in Oncology

September 28th 2025

Brian P. Mulherin, MD, discusses how artificial intelligence is helping shape smarter cancer care.

Five Under 5: Top Oncology Videos for the Week of 9/21

September 28th 2025

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

Dr Wilfong on the Potential Use of AI Prediction Models to Improve Palliative Care in Oncology

September 28th 2025

Lalan Wilfong, MD, expands on the value of AI prediction models for consensus on patient prognosis and better end-of-life care in oncology.

Dr Flora on the Potential Role of AI in Clinical Trial Screening and Design for Oncology

September 28th 2025

Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.

Simplifying Care Navigation in Oncology: A Painless Path to Better Support

September 28th 2025

Lalan Wilfong, MD, discusses the patient- and provider-facing implications that may result from renewed focus on improving care navigation in oncology.

Flora Charts the Future of AI in Community Cancer Care

September 27th 2025

Doug Flora, MD, FACC, LSSBB, explains how AI is transforming cancer care, urging oncologists to engage and guide its responsible use.

The OncFive: Top Oncology Articles for the Week of 9/21

September 27th 2025

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Dr Beck on the FDA Approval of Subcutaneous Pembrolizumab in Solid Tumors

September 25th 2025

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab and berahyaluronidase for use across all adult and solid-tumor indications.

A400/EP0031 NDA Accepted for Review in China for RET Fusion–Positive NSCLC

September 25th 2025

China’s NMPA has accepted for review a new drug application for A400/EP0031 in patients with RET fusion–positive non–small cell lung cancer.

SHR-4849 Shows Preliminary Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 Shows Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

KN026 NDA in Pretreated HER2+ Gastric or GEJ Cancer Accepted by NMPA for Review

September 17th 2025

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

Rezatapopt Elicits Responses in Several Solid Tumors Harboring a TP53 Y220C Mutation

September 15th 2025

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

Nadofaragene Firadenovec NDA Accepted for Review in Japan for BCG-Unresponsive NMIBC

September 15th 2025

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.

IDE397 Plus Sacituzumab Govitecan Elicits Responses in MTAP-Deletion Urothelial Cancer

September 15th 2025

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Tarlatamab Plus Anti–PD-L1 as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

September 15th 2025

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

September 15th 2025

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.